Explore Ranbaxy
Latest News
-
Ranbaxy Announces Conclusion Of Previously Disclosed Investigation By U.S. Department Of Justice
Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), today announced that a previously disclosed investigation by the U.S. Department… -
Ranbaxy Q1 CY 2013 Sales Rs.24,398 Mn. Base business grows by over 10%
Focus continues in branded markets and differentiated products The Board of Directors of Ranbaxy Laboratories Limited (RLL, NSE: RANBAXY, BSE:… -
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced synergy in Brazil to expand… -
Ranbaxy to market Desvenlafaxine Base Extended Release Tablets in The U.S.
Enters into an in-licensing business agreement with Alembic Princeton, NJ – March 05, 2013 — Ranbaxy Pharmaceuticals Inc. (RPI), a… -
RANBAXY SURPASS 2012 GUIDANCE; CROSSES RS.120 BN IN GLOBAL SALES
Q4 CY 2012 Sales Rs.26,708 Mn CY 2012 Sales Rs.123 Bn, EBITDA Rs.18,227 Mn EBITDA margin 15%. Sales growth of… -
DAIICHI SANKYO AND RANBAXY TO LEVERAGE SYNERGIES IN THAILAND
Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Ranbaxy Laboratories Limited (Ranbaxy) today announced their intention to integrate their business operations… -
RANBAXY LAUNCHES ABSORICA™ (ISOTRETINOIN) CAPSULES IN THE U.S. HEALTHCARE MARKET
Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the sales and promotion launch… -
RANBAXY DELIVERS STRONG OVERALL BUSINESS PERFORMANCE; IMPROVEMENT IN BASE BUSINESS SALES AND MARGINS
Q3 CY 2012 Sales Rs.26,514 Mn ($480 Mn), EBITDA Rs.4,179 Mn ($76 Mn) EBITDA margin 16%; Sales growth of 31%…
Ranbaxy Global ▼










